Impact of Initial Treatment and Prognostic Factors on Post-Progression Survival in BRAF-Mutated Metastatic Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Impact of Initial Treatment and Prognostic Factors on Postprogression Survival in BRAF-Mutated Metastatic Melanoma Treated With Dacarbazine or Vemurafenib ± Cobimetinib: A Pooled Analysis of Four Clinical Trials
J Transl Med 2020 Aug 03;18(1)294, PA Ascierto, A Ribas, J Larkin, GA McArthur, KD Lewis, A Hauschild, KT Flaherty, E McKenna, Q Zhu, Y Mun, B DrénoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.